Latest Breaking News On - Gene therapy trial - Page 1 : comparemela.com

MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

14.03.2023 - - Announced positive clinical data from AQUAx AAV-hAQP1 Phase 1 trial for treatment of Grade 2/3 Radiation-Induced Xerostomia in December 2022 - Announced positive top-line data from the MGT009 Phase 1/2 clinical study demonstrating safety and .

United statesUnited kingdomCity ofJason bracoBotaretigene sparoparvovecAmerican academy of ophthalmology annual meetingLifesci communicationsMeiragtx holdingsEuropean society of geneJanssen pharmaceuticals incJanssen pharmaceutical companies of johnsonAlexandria forbesEuropean societyCell therapyAnnual congressLumeos phase

MeiraGTx Holdings plc (MGTX) Announces $25M Investment from Johnson & Johnson Innovation

MeiraGTx Holdings plc (MGTX) Announces $25M Investment from Johnson & Johnson Innovation
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomCity ofJason bracoBotaretigene sparoparvovecEuropean society of geneJanssen pharmaceuticals incAmerican academy of ophthalmologyJanssen pharmaceutical companies of johnsonAmerican academy of ophthalmology annual meetingMeiragtx holdingsLifesci communicationsAlexandria forbesAmerican academyJanssen pharmaceuticalsJanssen pharmaceutical companies

NTSAD to honor Guangping Gao for lifetime work on Canavan disease, as gene therapy trial shows promise

Guangping Gao, PhD, will be honored by the National Tay-Sachs & Allied Diseases Association for his work in identifying the Canavan gene, revitalizing gene therapy, and his many accomplishments leading to potential treatments for Canavan disease.

United statesBio pharmaFlorian eichlerGuangping gaoDrug administrationHarvard medical schoolHospital centerPenelope booth rockwell professor in biomedical researchNational tay sachs allied diseases associationEuropean unionLi weibo institute for rare diseases researchHorae gene therapy centerNational tay sachsAllied diseases associationPenelope booth rockwell professorBiomedical research

MeiraGTx Holdings plc (MGTX) ReportS Strong Phase 1/2 Data for Botaretigene Sparoparvovec

MeiraGTx Holdings plc (MGTX) ReportS Strong Phase 1/2 Data for Botaretigene Sparoparvovec
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesJason bracoMichel michaelidesUniversity college londonJanssen pharmaceuticals incDrug administrationAmerican academy of ophthalmologyJanssen pharmaceutical companies of johnsonPh dlifesci communicationsAmerican academy of ophthalmology annual meetingMeiragtx holdingsInstitute of ophthalmologyEuropean medicines agencyRetina subspecialty dayAmerican academy

Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of

Results from the Phase 1/2 MGT009 study presented at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting set the stage for Phase 3 LUMEOS trial.

United kingdomUnited statesCity ofJason bracoMichel michaelidesBotaretigene sparoparvovecUniversity college londonJanssen pharmaceuticals incDrug administrationAmerican academy of ophthalmologyJanssen pharmaceutical companies of johnsonAmerican academy of ophthalmology annual meetingLifesci communicationsMeiragtx holdingsInstitute of ophthalmologyEuropean medicines agency